Trial Profile
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Adverse reactions
- Acronyms COBRRA
- 20 Apr 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 20 Apr 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 25 Mar 2020 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.